

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY.

ABILIFY® (aripiprazole) Tablets

ABILIFY® DISCMELT™ (aripiprazole) Orally Disintegrating Tablets

ABILIFY® (aripiprazole) Oral Solution

ABILIFY® (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY

Initial U.S. Approval: 2002

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of patients with dementia-related psychosis. (5.1)

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

See full prescribing information for complete boxed warning. Children, adolescents, and young adults taking antidepressants for Major Depressive Disorder and other psychiatric disorders are at increased risk of suicidal thinking and behavior. (5.2)

RECENT MAJOR CHANGES

Boxed Warning, Suicidality and Antidepressant Drugs	11/2007
Indications and Usage, Pediatric (13 to 17 yrs) Schizophrenia (1.1)	10/2007
Dosage and Administration, Pediatric Schizophrenia (2.1)	10/2007
Indications and Usage, Adjunctive Treatment in Adults with Major Depressive Disorder (1.3)	11/2007
Dosage and Administration, Adjunctive Treatment in Adults with Major Depressive Disorder (2.3)	11/2007
Warnings and Precautions, Clinical Worsening and Suicide Risk (5.2)	11/2007

INDICATIONS AND USAGE

ABILIFY is an atypical antipsychotic indicated as oral formulations for:

- Treatment of Schizophrenia in adults and adolescents aged 13-17 years (1.1)
- Treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults (1.2)
- Adjunctive Treatment of Major Depressive Disorder in adults (1.3) as an injection for:
- Treatment of adults with agitation associated with Schizophrenia or Bipolar I Disorder, manic or mixed (1.4)

DOSAGE AND ADMINISTRATION

	Initial Dose	Recommended Dose	Maximum Dose
Schizophrenia-adults (2.1)	10-15 mg /day	10-15 mg /day	30 mg /day
Schizophrenia – adolescents (2.1)	2 mg /day	10 mg /day	30 mg /day
Bipolar Mania–adults (2.2)	15-30 mg /day	15-30 mg /day	30 mg /day
As an adjunct to antidepressants for the treatment of Major Depressive Disorder (2.4)	2-5 mg /day	5-10 mg /day	15 mg/day
Agitation associated with Schizophrenia or Bipolar Mania–adults (2.4)	9.75 mg /1.3 mL injected IM		30 mg /day injected IM

- ABILIFY oral formulations: Administer once daily without regard to meals (2)
- ABILIFY injection: Wait at least 2 hours between doses. Maximum daily dose 30 mg (2.4)

DOSAGE FORMS AND STRENGTHS

- Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg (3)
- Orally Disintegrating Tablets: 10 mg and 15 mg (3)
- Oral Solution: 1 mg/mL (3)
- Injection: 9.75 mg/1.3 mL single-dose vial (3)

CONTRAINDICATIONS

Known hypersensitivity to ABILIFY (4)

WARNINGS AND PRECAUTIONS

- *Elderly Patients with Dementia-Related Psychosis*: Increased incidence of cerebrovascular adverse events (eg, stroke, transient ischemic attack, including fatalities) (5.1)
- *Suicidality and Antidepressants*: Increased risk of suicidality in children, adolescents, and young adults with Major Depressive Disorder (5.2)
- *Neuroleptic Malignant Syndrome*: Manage with immediate discontinuation and close monitoring (5.3)
- *Tardive Dyskinesia*: Discontinue if clinically appropriate (5.4)
- *Hyperglycemia and Diabetes Mellitus*: Monitor glucose regularly in patients with and at risk for diabetes (5.5)
- *Orthostatic Hypotension*: Use with caution in patients with known cardiovascular or cerebrovascular disease (5.6)
- *Seizures/Convulsions*: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (5.7)
- *Potential for Cognitive and Motor Impairment*: Use caution when operating machinery (5.8)
- *Suicide*: Closely supervise high-risk patients (5.10)

ADVERSE REACTIONS

Commonly observed adverse reactions (incidence \geq 5% and at least twice that for placebo) were (6.2):

- Adult patients with Schizophrenia: akathisia
- Pediatric patients (13 to 17 yrs) with Schizophrenia: extrapyramidal disorder, somnolence, and tremor
- Adult patients with Bipolar Mania: constipation, akathisia, sedation, tremor, restlessness, and extrapyramidal disorder
- Adult patients with Major Depressive Disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision
- Adult patients with agitation associated with Schizophrenia or Bipolar Mania: nausea.

To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

- *Strong CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine) inhibitors will increase ABILIFY drug concentrations; reduce ABILIFY dose by one-half when used concomitantly (2.5, 7.1), except when used as adjunctive treatment with antidepressants (2.5)*
- *CYP3A4 inducers (e.g., carbamazepine) will decrease ABILIFY drug concentrations; double ABILIFY dose when used concomitantly (2.5, 7.1)*

See 17 for PATIENT COUNSELING INFORMATION and MEDICATION GUIDE

Revised: 11/2007

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

1 INDICATIONS AND USAGE

- 1.1 Schizophrenia
- 1.2 Bipolar Disorder
- 1.3 Adjunctive Treatment of Major Depressive Disorder
- 1.4 Agitation Associated with Schizophrenia or Bipolar Mania

2 DOSAGE AND ADMINISTRATION

- 2.1 Schizophrenia
- 2.2 Bipolar Disorder
- 2.3 Adjunctive Treatment of Major Depressive Disorder
- 2.4 Agitation Associated with Schizophrenia or Bipolar Mania (Intramuscular Injection)
- 2.5 Dosage Adjustment
- 2.6 Dosing of Oral Solution
- 2.7 Dosing of Orally Disintegrating Tablets

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Use in Elderly Patients with Dementia-Related Psychosis
- 5.2 Clinical Worsening and Suicide Risk
- 5.3 Neuroleptic Malignant Syndrome (NMS)
- 5.4 Tardive Dyskinesia
- 5.5 Hyperglycemia and Diabetes Mellitus
- 5.6 Orthostatic Hypotension
- 5.7 Seizures/Convulsions
- 5.8 Potential for Cognitive and Motor Impairment
- 5.9 Body Temperature Regulation
- 5.10 Suicide
- 5.11 Dysphagia
- 5.12 Use in Patients with Concomitant Illness

6 ADVERSE REACTIONS

- 6.1 Overall Adverse Reactions Profile
- 6.2 Clinical Studies Experience
- 6.3 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Potential for Other Drugs to Affect ABILIFY
- 7.2 Potential for ABILIFY to Affect Other Drugs

- 7.3 Drugs Having No Clinically Important Interactions with ABILIFY

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- 8.8 Gender
- 8.9 Race
- 8.10 Smoking

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse and Dependence

10 OVERDOSAGE

- 10.1 Human Experience
- 10.2 Management of Overdosage

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Schizophrenia
- 14.2 Bipolar Disorder
- 14.3 Adjunctive Treatment of Major Depressive Disorder
- 14.4 Agitation Associated with Schizophrenia or Bipolar Mania

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis [*see WARNINGS AND PRECAUTIONS (5.1)*].

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. ABILIFY is not approved for use in pediatric patients with depression [*see WARNINGS AND PRECAUTIONS (5.2)*].

1 INDICATIONS AND USAGE

1.1 Schizophrenia

Adults

ABILIFY is indicated for acute and maintenance treatment of Schizophrenia [see *CLINICAL STUDIES (14.1)*].

Adolescents

ABILIFY is indicated for the treatment of Schizophrenia in adolescents 13 to 17 years of age [see *CLINICAL STUDIES (14.1)*].

1.2 Bipolar Disorder

Adults

ABILIFY is indicated for acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features [see *CLINICAL STUDIES (14.2)*].

1.3 Adjunctive Treatment of Major Depressive Disorder

Adults

ABILIFY is indicated for use as an adjunctive treatment to antidepressants for Major Depressive Disorder [see *CLINICAL STUDIES (14.3)*].

1.4 Agitation Associated with Schizophrenia or Bipolar Mania

Adults

ABILIFY Injection is indicated for the treatment of agitation associated with Schizophrenia or Bipolar Disorder, manic or mixed. "Psychomotor agitation" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner tension." Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care (e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior), leading clinicians to the use of intramuscular antipsychotic

medications to achieve immediate control of the *agitation* [see *CLINICAL STUDIES (14.4)*].

2 DOSAGE AND ADMINISTRATION

2.1 Schizophrenia

Usual Dose

Adults

The recommended starting and target dose for ABILIFY is 10 mg/day or 15 mg/day administered on a once-a-day schedule without regard to meals. ABILIFY has been systematically evaluated and shown to be effective in a dose range of 10 mg/day to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 mg/day or 15 mg/day were not more effective than 10 mg/day or 15 mg/day. Dosage increases should not be made before 2 weeks, the time needed to achieve steady state [see *CLINICAL STUDIES (14.1)*].

Adolescents

The recommended target dose of ABILIFY is 10 mg/day. Aripiprazole was studied in pediatric patients 13 to 17 years of age with Schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. ABILIFY can be administered without regard to meals [see *CLINICAL STUDIES (14.1)*].

Maintenance Therapy

Adults

While there is no body of evidence available to answer the question of how long a patient treated with aripiprazole should remain on it, systematic evaluation of patients with Schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer, were discontinued from those medications, and were then administered ABILIFY 15 mg/day and observed for relapse during a period of up to 26 weeks, has demonstrated a benefit of such maintenance treatment [see *CLINICAL*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.